Psilocybin Research and Contemplative-State Parallels

The psychedelic-renaissance literature (Johns Hopkins, NYU, Imperial College) routinely frames psilocybin experiences against Eastern contemplative states — unity experiences, ego-dissolution, and the mysticism scales’ history.

Summary

Griffiths’s 2006/2011 Hopkins studies revived psilocybin research; the mysticism-scale scoring of sessions (Hood’s M-scale, built partly on Stace’s comparative-mysticism framework) found “complete Mystical Experience” predictors of therapeutic outcome; ego-dissolution measures (the Ego-Dissolution Inventory) parallel contemplative anatta reports.

Key Findings

Single high-dose sessions produce enduring increases in well-being and openness (the personality-trait change finding — openness’s long-term shift); mystical-type experience quality predicts outcomes; depression and addiction trials show durable effects in phase-2 designs.

Methodology

Controlled-session designs with preparatory and integrative frameworks; expectancy/setting effects substantial; blinding limits.

Criticism/Limitations

The contemplative-parallel framing criticized (drug-state vs developed-trait states differ in stability and ethics); adverse-event profiles in vulnerable populations; regulatory contexts.

Verification notes

• The Hopkins corpus and the M-scale history summarized accurately.
• Audited against the clinical literature (September 2026).